Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: Safety and re-challenge

Acta Neurologica Taiwanica

Volumn 16, Issue 3, 2007, Pages 163-167

  Chen, Yu Wei ^a,b   Lai, Hsin Wen ^a   Wang, Tzung Dau ^b  

^a LI SHIN HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatitis C; Hyperlipidemia; Safety; Statin

Indexed keywords

AMOXICILLIN; ATORVASTATIN; CLARITHROMYCIN; CLOPIDOGREL; ESOMEPRAZOLE; FLUINDOSTATIN; GLIMEPIRIDE; IRBESARTAN; LIVER ENZYME; SIMVASTATIN;

AGED; ANAMNESIS; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; HYPERTENSION; NUCLEAR MAGNETIC RESONANCE IMAGING; SIDE EFFECT; TREATMENT DURATION; VERTIGO;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER;

EID: 35048875811     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
3. Chen DS, Kuo GC, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:817-22.
4. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:290-6.
5. Lin CC, Hwang SJ, Chiou ST, et al. The prevalence and risk factors analysis of serum antibody to hepatitis C virus in the elders in northeast Taiwan. J Chin Med Assoc 2003;66:103-8.
6. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991;91:25S-30S.
7. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85:15E-9E.
8. Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 2004;12:222-34.
9. Anfossi G, Massucco P, Bonomo K, et al. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004;14:215-24.
10. Andrade SE, Donahue JG, Chan KA, et al. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiol Drug Saf 2003;12:307-13.
11. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163:688-92.
12. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618-24.
13. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41.
14. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71:58-62.
15. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
16. Gibson K, Rindone JP. Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol 2005;96:1278-9.
17. Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002;97:115-21.